---
title: Identification of CETP as a Marker of Atherosclerosis
nct_id: NCT02081066
overall_status: COMPLETED
phase: NA
sponsor: Institut National de la Santé Et de la Recherche Médicale, France
study_type: INTERVENTIONAL
primary_condition: Cardiovascular Disease
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02081066.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02081066"
ct_last_update_post_date: 2026-04-24
last_seen_at: "2026-05-12T07:08:17.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Identification of CETP as a Marker of Atherosclerosis

**Official Title:** Relationship Between Endogenous CETP Activity and Atherosclerosis Distribution in Patients With High Cardiovascular Risk

**NCT ID:** [NCT02081066](https://clinicaltrials.gov/study/NCT02081066)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 99
- **Lead Sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Conditions:** Cardiovascular Disease
- **Start Date:** 2014-09-25
- **Completion Date:** 2020-09
- **CT.gov Last Update:** 2026-04-24

## Brief Summary

The reverse cholesterol transport (RCT) pathway, which involves the centripetal movement of free cholesterol from peripheral tissues, including the vessel wall, to the liver represent the primary mechanism by which HDL protects against atherosclerosis and by which it may induce plaque regression. Recent data reveal that the capacity of HDL to efflux cholesterol from macrophages, a metric of HDL function reflecting the initial step of the RCT, is clinically relevant, displaying a strong inverse association with both carotid intima-media thickness and the severity of angiographic CAD; such observations were independent of HDL-C levels.

In human, the Cholesteryl Ester Transfer Protein (CETP), represents a key protein of the RCT pathway and mediates redistribution of neutral lipids between lipoproteins, has been identified as a potential therapeutic target against atherosclerosis. It is known that CETP activity correlates with HDL-C levels and represents a key modulator of the ability of whole plasma to mediate free cholesterol efflux from human macrophages.

Recent studies showed that 23% of endogenous plasma CETP activity variability is explained by plasma LDL-C (12.0%), HDL-C (6.4%) and TG (4.4%) whereas sex and BMI accounted together for only 0.7% of its variability. Scoring patients for cardiovascular risk on the basis of their plasma lipid levels (TC, TG, LDL-C and HDL-C), revealed that patients with high cardiovascular risk (score ≥3) displayed a mean endogenous plasma CETP activity above 34%. Therefore plasma CETP activity represents a potent indicator of cardiovascular risk in patients with metabolic disorders since it integrates major independent risk factors.

The objective of this study is to decipher the relationship between CETP, HDL efflux capacity and the development of atherosclerosis in humans in order to identify CETP as a potent biomarker of atherosclerosis distribution.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Signed informed consent prior to initiation of the study
* Men and women aged 18 or more years
* Patients displaying at least one abnormal plasma lipid parameter and/or receiving a lipid-lowering therapy unchanged for at least 3 months.

Exclusion Criteria:

* Current significant renal disease, including: nephrotic syndrome; chronic renal failure and/or serum creatinine \>1.7 x upper limit of the reference range (ULRR)
* Uncontrolled hypothyroidism defined as TSH \>2 x ULRR
* Active hepatobiliary disease, including chronic hepatitis B or hepatitis C infection (confirmed by serology); or an aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) \>3.0 x ULRR
* Any prior history of malignancy or current cancer
* Current chronic or acute inflammatory syndrome defined as CRP\>10 mg/l
```

## Arms

- **patients with cardiovascular risk factors** (OTHER)

## Interventions

- **cardiovascular risk factors** (OTHER)

## Primary Outcomes

- **Endogenous CETP activity** _(time frame: Day 1)_
- **carotid intima-media thickness** _(time frame: day 1)_
- **Coronary calcium score** _(time frame: Day 1)_

## Secondary Outcomes

- **plasma efflux capacity from human macrophage** _(time frame: Day 1)_
- **HDL genetic variant** _(time frame: Day1)_

## Locations (1)

- Inserm Umrs1166, Paris, France

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.inserm umrs1166|paris||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02081066.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02081066*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*